Cyclo Therapeutics Stock Last Dividend Paid

CYTHW Stock

USD 0.14 0.00 0.00%

Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cyclo Therapeutics Company Last Dividend Paid Analysis

Cyclo Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

Cyclo Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for Cyclo Therapeutics is extremely important. It helps to project a fair market value of Cyclo Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Cyclo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclo Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Current Deferred Revenue	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt	Short Long Term Debt	Net Tangible Assets
Total Assets		0.85	-0.96	-0.71	0.81	0.68	0.73	0.99	0.4	-0.28	-0.42	-0.3	-0.52	0.8	0.7	0.91	0.9	-0.79	-0.67	0.65	-0.48
Total Stockholder Equity	0.85		-0.89	-0.3	0.45	0.79	0.28	0.84	-0.04	-0.23	-0.43	-0.23	-0.33	0.45	0.53	0.95	0.95	-0.65	-0.39	0.3	0.01
Net Debt	-0.96	-0.89		0.63	-0.79	-0.74	-0.62	-0.98	-0.22	0.2	0.37	0.22	0.63	-0.73	-0.72	-0.96	-0.95	0.77	0.58	-0.53	0.32
Retained Earnings	-0.71	-0.3	0.63		-0.91	-0.3	-0.94	-0.74	-0.82	0.24	0.29	0.28	0.7	-0.98	-0.65	-0.46	-0.44	0.77	0.89	-0.92	0.72
Accounts Payable	0.81	0.45	-0.79	-0.91		0.44	0.93	0.85	0.58	-0.24	-0.13	-0.27	-0.76	0.91	0.76	0.61	0.59	-0.67	-0.71	0.75	-0.67
Net Receivables	0.68	0.79	-0.74	-0.3	0.44		0.23	0.7	-0.14	-0.25	-0.07	-0.25	-0.46	0.41	0.31	0.79	0.8	-0.38	-0.45	0.31	0.03
Total Liab	0.73	0.28	-0.62	-0.94	0.93	0.23		0.73	0.79	-0.23	-0.21	-0.28	-0.55	0.91	0.63	0.44	0.42	-0.63	-0.76	0.86	-0.85
Total Current Assets	0.99	0.84	-0.98	-0.74	0.85	0.7	0.73		0.38	-0.24	-0.39	-0.26	-0.63	0.83	0.73	0.92	0.91	-0.81	-0.68	0.65	-0.46
Short Term Debt	0.4	-0.04	-0.22	-0.82	0.58	-0.14	0.79	0.38		-0.18	-0.29	-0.22	-0.28	0.76	0.34	0.05	0.02	-0.54	-0.75	0.82	-0.77
Intangible Assets	-0.28	-0.23	0.2	0.24	-0.24	-0.25	-0.23	-0.24	-0.18		-0.33	0.99	0.34	-0.21	-0.18	-0.13	-0.13	0.17	0.18	-0.18	0.08
Common Stock	-0.42	-0.43	0.37	0.29	-0.13	-0.07	-0.21	-0.39	-0.29	-0.33		-0.31	-0.08	-0.41	-0.3	-0.48	-0.48	0.71	0.45	-0.38	0.12
Short Term Investments	-0.3	-0.23	0.22	0.28	-0.27	-0.25	-0.28	-0.26	-0.22	0.99	-0.31		0.35	-0.24	-0.21	-0.13	-0.12	0.19	0.22	-0.25	0.1
Current Deferred Revenue	-0.52	-0.33	0.63	0.7	-0.76	-0.46	-0.55	-0.63	-0.28	0.34	-0.08	0.35		-0.68	-0.58	-0.46	-0.46	0.57	0.54	-0.49	0.27
Capital Surpluse	0.8	0.45	-0.73	-0.98	0.91	0.41	0.91	0.83	0.76	-0.21	-0.41	-0.24	-0.68		0.69	0.6	0.58	-0.85	-0.91	0.89	-0.66
Property Plant Equipment	0.7	0.53	-0.72	-0.65	0.76	0.31	0.63	0.73	0.34	-0.18	-0.3	-0.21	-0.58	0.69		0.61	0.6	-0.68	-0.46	0.46	-0.26
Net Invested Capital	0.91	0.95	-0.96	-0.46	0.61	0.79	0.44	0.92	0.05	-0.13	-0.48	-0.13	-0.46	0.6	0.61		1.0	-0.73	-0.49	0.4	-0.18
Net Working Capital	0.9	0.95	-0.95	-0.44	0.59	0.8	0.42	0.91	0.02	-0.13	-0.48	-0.12	-0.46	0.58	0.6	1.0		-0.72	-0.48	0.38	-0.15
Capital Stock	-0.79	-0.65	0.77	0.77	-0.67	-0.38	-0.63	-0.81	-0.54	0.17	0.71	0.19	0.57	-0.85	-0.68	-0.73	-0.72		0.78	-0.69	0.35
Long Term Debt	-0.67	-0.39	0.58	0.89	-0.71	-0.45	-0.76	-0.68	-0.75	0.18	0.45	0.22	0.54	-0.91	-0.46	-0.49	-0.48	0.78		-0.95	0.51
Short Long Term Debt	0.65	0.3	-0.53	-0.92	0.75	0.31	0.86	0.65	0.82	-0.18	-0.38	-0.25	-0.49	0.89	0.46	0.4	0.38	-0.69	-0.95		-0.66
Net Tangible Assets	-0.48	0.01	0.32	0.72	-0.67	0.03	-0.85	-0.46	-0.77	0.08	0.12	0.1	0.27	-0.66	-0.26	-0.18	-0.15	0.35	0.51	-0.66

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict Cyclo Therapeutics

Cyclo Dividend Paid And Capex Coverage Ratio

Dividend Paid And Capex Coverage Ratio

(6,353.63)

At this time, Cyclo Therapeutics' Dividend Paid And Capex Coverage Ratio is fairly stable compared to the past year.

Based on the recorded statements, Cyclo Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Portfolio Dashboard Now

Portfolio Dashboard

Portfolio dashboard that provides centralized access to all your investments

All Next

Launch Module

Cyclo Fundamentals

	Return On Equity	-226.64
	Return On Asset	-2.82
	Operating Margin	(45.78) %
	Number Of Shares Shorted	100
	Revenue	1.08 M
	EBITDA	(20.03 M)
	Net Income	(20.06 M)
	Cash And Equivalents	2.24 M
	Cash Per Share	1.32 X
	Total Debt	1.03 M
	Current Ratio	0.87 X
	Book Value Per Share	0.17 X
	Cash Flow From Operations	(16.19 M)
	Beta	-0.38
	Market Capitalization	62.76 M
	Total Asset	13.25 M
	Retained Earnings	(83.86 M)
	Working Capital	3.85 M
	Net Asset	13.25 M

About Cyclo Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC